年内“翻倍基”多达23只,医药主题基金占据“半壁江山”

北京商报
30 Jul

在年内大盘整体上涨的背景下,部分权益类基金也交出了亮眼的成绩单。公开数据显示,截至7月29日,共有23只基金(份额分开计算,下同)的年内收益率实现翻倍,其中有七成为医药相关基金。若拉长时间至近一年来看,则有多达134只“翻倍基”,其中,医药相关基金占比超四成,收益率最高超160%。展望后市,业内人士仍看好创新药等细分方向,但也有观点提醒需注意短期回调可能带来的风险。15只医药基金年内收益翻倍7月...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10